These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 11461070)
21. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Kroon HM; Lin DY; Kam PC; Thompson JF Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288 [TBL] [Abstract][Full Text] [Related]
22. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234 [TBL] [Abstract][Full Text] [Related]
23. Isolated limb perfusion for unresectable melanoma of the extremities. Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572 [TBL] [Abstract][Full Text] [Related]
24. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638 [TBL] [Abstract][Full Text] [Related]
25. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309 [TBL] [Abstract][Full Text] [Related]
26. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS; J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537 [TBL] [Abstract][Full Text] [Related]
27. In-transit Merkel cell carcinoma treated with isolated limb perfusion or isolated limb infusion: a case series of 12 patients. Zeitouni NC; Giordano CN; Kane JM Dermatol Surg; 2011 Mar; 37(3):357-64. PubMed ID: 21324044 [TBL] [Abstract][Full Text] [Related]
28. [Regional isolated perfusion: also applicable in elderly patients]. Noorda EM; Vrouenraets BC; Nieweg OE; Kroon BB Ned Tijdschr Geneeskd; 2003 Mar; 147(12):529-33. PubMed ID: 12693077 [TBL] [Abstract][Full Text] [Related]
29. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution. Huismans AM; Kroon HM; Kam PC; Thompson JF Ann Surg Oncol; 2011 Jul; 18(7):1877-83. PubMed ID: 21499810 [TBL] [Abstract][Full Text] [Related]
33. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498 [TBL] [Abstract][Full Text] [Related]
35. TNF-based limb perfusion for cutaneous melanoma in transit metastases: suggestions for modification of the perfusional schedule. Rossi CR; Foletto M; Mocellin S; Pilati PL; Campana L; Rubello D; Lise M J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):103-7. PubMed ID: 16767915 [TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Kroon HM; Lin DY; Kam PC; Thompson JF Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677 [TBL] [Abstract][Full Text] [Related]
37. Isolated hepatic perfusion for liver metastases of malignant melanoma. Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648 [TBL] [Abstract][Full Text] [Related]
38. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Thompson JF; Lai DT; Ingvar C; Kam PC Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596 [TBL] [Abstract][Full Text] [Related]
39. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721 [TBL] [Abstract][Full Text] [Related]
40. Future directions in regional treatment strategies for melanoma and sarcoma. Beasley GM; Ross MI; Tyler DS Int J Hyperthermia; 2008 May; 24(3):301-9. PubMed ID: 18393007 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]